Akari Therapeutics (AKTX) EBIAT (2014 - 2026)
Akari Therapeutics' (AKTX) quarterly EBIAT came in at -$14.5 million in Q1 2026, down 290.15% year-on-year from $7.6 million in Q1 2025, and down 172.84% quarter-over-quarter from -$5.3 million in Q4 2025.
Akari Therapeutics (AKTX) EBIAT (2014 - 2026) Analysis & Trends
Akari Therapeutics has disclosed EBIAT across 9 years of filings, most recently posting -$14.5 million for Q1 2026.
- EBIAT for Q1 2026 came in at -$14.5 million, down 290.15% year-over-year; the trailing twelve-month figure through Mar 2026 was -$28.0 million (up 81.8% YoY), and the FY2025 annual result was -$17.3 million, up 12.6% from the prior year.
- EBIAT came in at -$14.5 million for Q1 2026 at Akari Therapeutics, down from -$5.3 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $1.0 million in Q1 2023 to a low of -$140.0 million in Q4 2024.
- The 4-year median for EBIAT is -$4.1 million (2023), against an average of -$15.2 million.
- Across the five-year window, EBIAT tumbled 3283.11% in 2024 and soared 96.22% in 2025, its largest moves.
- Akari Therapeutics' EBIAT stood at -$4.1 million in 2023, then sank by 3283.11% to -$140.0 million in 2024, then jumped by 96.22% to -$5.3 million in 2025, then tumbled by 172.84% to -$14.5 million in 2026.
- The last three EBIAT figures came in at -$14.5 million (Q1 2026), -$5.3 million (Q4 2025), and -$6.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.59 Bn | 54.83 Bn | 3.31 Bn | 727.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.46 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Sep 30, 2025 | -6.40 Mn |
| Jun 30, 2025 | -1.90 Mn |
| Mar 31, 2025 | -3.71 Mn |
| Dec 31, 2024 | -139.99 Mn |
| Sep 30, 2024 | -2.90 Mn |
| Jun 30, 2024 | -7.56 Mn |
| Mar 31, 2024 | -5.57 Mn |
| Dec 31, 2023 | -4.14 Mn |
| Sep 30, 2023 | -2.87 Mn |
| Jun 30, 2023 | -4.00 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2020 | -6.81 Mn |
| Sep 30, 2020 | 913,454.00 |
| Jun 30, 2020 | -7.44 Mn |
| Mar 31, 2020 | -3.75 Mn |
| Dec 31, 2019 | -7.83 Mn |
| Sep 30, 2019 | -2.88 Mn |
| Jun 30, 2019 | -5.95 Mn |